Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | HIF-2α as an alternate therapeutic target in ER+ breast cancer

Bora Lim • 12 Dec 2024
SABCS 2024
Breast Cancer

Bora Lim, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the use of CDK4/6 inhibitors as a first-line treatment option for estrogen receptor-positive (ER+) breast cancer. The identification of an alternate pathway as a therapeutic target could overcome treatment resistance by controlling ER. HIF-2α (hypoxia-inducible factor-2α) is a potential novel target in ER+ breast cancer and the prospect of achieving positive results from targeting this pathway could open up a new era of treatments for breast cancer. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Bora Lim

Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC
2:46
Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC
Bora Lim • 12 Dec 2024
LITESPARK-029: belzutifan with fulvestrant in ER+/HER2- breast cancer
1:57
LITESPARK-029: belzutifan with fulvestrant in ER+/HER2- breast cancer
Bora Lim • 12 Dec 2024
Highlights at SABCS 2021 for basic science and early-phase clinical trials
1:32
Highlights at SABCS 2021 for basic science and early-phase clinical trials
Bora Lim • 9 Dec 2021
Single-cell genomics and proteogenomics in cancer
1:49
Single-cell genomics and proteogenomics in cancer
Bora Lim • 9 Dec 2021

Related Videos

Recommendations for low-dose tamoxifen in pre- and postmenopausal women with breast cancer
0:55
Recommendations for low-dose tamoxifen in pre- and postmenopausal women with breast cancer
Andrea De Censi • 29 May 2026
Pre-pectoral IBBR and oncologic safety following mastectomy
1:20
Pre-pectoral IBBR and oncologic safety following mastectomy
Walter Weber • 30 May 2026
Low-dose tamoxifen could prevent breast cancer in at-risk young premenopausal women
0:45
Low-dose tamoxifen could prevent breast cancer in at-risk young premenopausal women
Andrea De Censi • 29 May 2026
Results from the PREPEC trial support pre-pectoral positioning for IBBR following mastectomy
0:48
Results from the PREPEC trial support pre-pectoral positioning for IBBR following mastectomy
Walter Weber • 30 May 2026
The content of VJOncology is intended for healthcare professionals